These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

505 related articles for article (PubMed ID: 1462166)

  • 1. The anthracyclines: will we ever find a better doxorubicin?
    Weiss RB
    Semin Oncol; 1992 Dec; 19(6):670-86. PubMed ID: 1462166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I and II agents in cancer therapy: I. Anthracyclines and related compounds.
    Wadler S; Fuks JZ; Wiernik PH
    J Clin Pharmacol; 1986; 26(7):491-509. PubMed ID: 2944917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical studies with new anthracyclines: epirubicin, idarubicin, esorubicin.
    Hurteloup P; Ganzina F
    Drugs Exp Clin Res; 1986; 12(1-3):233-46. PubMed ID: 3525075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of anthracyclines in the era of targeted therapy.
    Cortés-Funes H; Coronado C
    Cardiovasc Toxicol; 2007; 7(2):56-60. PubMed ID: 17652804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New anthracycline antitumor antibiotics.
    Muggia FM; Green MD
    Crit Rev Oncol Hematol; 1991; 11(1):43-64. PubMed ID: 1831987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anthracyclines in the treatment of cancer. An overview.
    Hortobágyi GN
    Drugs; 1997; 54 Suppl 4():1-7. PubMed ID: 9361955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
    Seymour L; Bramwell V; Moran LA
    Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Therapy of acute leukemia: contribution of the new anthracyclinic drugs].
    Lambertenghi-Deliliers G; Colajori E; Annaloro C; Polli EE
    Recenti Prog Med; 1985; 76(7-8):392-7. PubMed ID: 3906794
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparison of cardiac events associated with liposomal doxorubicin, epirubicin and doxorubicin in breast cancer: a Bayesian network meta-analysis.
    Yamaguchi N; Fujii T; Aoi S; Kozuch PS; Hortobagyi GN; Blum RH
    Eur J Cancer; 2015 Nov; 51(16):2314-20. PubMed ID: 26343314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of the structure of new anthracycline antibiotics on their biological properties.
    Wasowska M; Oszczapowicz I; Wietrzyk J; Opolski A; Madej J; Dzimira S; Oszczapowicz J
    Anticancer Res; 2005; 25(3B):2043-8. PubMed ID: 16158943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pharmacokinetics of new anthracyclines].
    Robert J
    Bull Cancer; 1988; 75(2):167-74. PubMed ID: 3282579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of the model of rat isolated perfused heart for the evaluation of anthracycline cardiotoxicity and its circumvention.
    Pouna P; Bonoron-Adèle S; Gouverneur G; Tariosse L; Besse P; Robert J
    Br J Pharmacol; 1996 Apr; 117(7):1593-9. PubMed ID: 8730759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Adriamycin and its analogs].
    Arcamone F
    Tumori; 1984 Apr; 70(2):113-9. PubMed ID: 6587651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Derivation of Anthracycline and Anthraquinone Equivalence Ratios to Doxorubicin for Late-Onset Cardiotoxicity.
    Feijen EAM; Leisenring WM; Stratton KL; Ness KK; van der Pal HJH; van Dalen EC; Armstrong GT; Aune GJ; Green DM; Hudson MM; Loonen J; Oeffinger KC; Robison LL; Yasui Y; Kremer LCM; Chow EJ
    JAMA Oncol; 2019 Jun; 5(6):864-871. PubMed ID: 30703192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New anthracycline analogs in advanced breast cancer.
    Bonfante V; Ferrari L; Brambilla C; Rossi A; Villani F; Crippa F; Valagussa P; Bonadonna G
    Eur J Cancer Clin Oncol; 1986 Nov; 22(11):1379-85. PubMed ID: 3470179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Dexrazoxane in patients with B-lymphomas or acute leukemias in the 2nd complete remission enables further therapy with cardiotoxic anthracyclines over recommended cumulative doses].
    Lemez P; Stejskal J; Cahová S; Holub M; Svítil P; Maresová J; Vásová I; Boudová L; Benesová V; Dvoráková D; Fisar J; Slavícek L
    Vnitr Lek; 2004 Jun; 50(6):438-46. PubMed ID: 15346637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anthracycline analogs: the past, present, and future.
    Weiss RB; Sarosy G; Clagett-Carr K; Russo M; Leyland-Jones B
    Cancer Chemother Pharmacol; 1986; 18(3):185-97. PubMed ID: 2948729
    [No Abstract]   [Full Text] [Related]  

  • 18. Recent advances in the prevention of anthracycline cardiotoxicity in childhood.
    Iarussi D; Indolfi P; Casale F; Coppolino P; Tedesco MA; Di Tullio MT
    Curr Med Chem; 2001 Nov; 8(13):1649-60. PubMed ID: 11562284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Doxorubicin-dependent reduction of ferrylmyoglobin and inhibition of lipid peroxidation: implications for cardiotoxicity of anticancer anthracyclines.
    Menna P; Salvatorelli E; Giampietro R; Liberi G; Teodori G; Calafiore AM; Minotti G
    Chem Res Toxicol; 2002 Sep; 15(9):1179-89. PubMed ID: 12230412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmaceutical Measures to Prevent Doxorubicin-Induced Cardiotoxicity.
    Liu H; Wang H; Xiang D; Guo W
    Mini Rev Med Chem; 2017; 17(1):44-50. PubMed ID: 27337969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.